The FDA's Office of Oncology Products has come in for stinging criticism from drug developers, advocates and even a US legislator over the use of surrogate endpoints. Has the agency struck the right balance between speed and caution? Malorye Allison investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allison, M. Trouble at the office. Nat Biotechnol 26, 967–969 (2008). https://doi.org/10.1038/nbt0908-967
Issue Date:
DOI: https://doi.org/10.1038/nbt0908-967
This article is cited by
-
The cancer vaccine roller coaster
Nature Biotechnology (2009)
-
Fresh from the biologic pipeline
Nature Biotechnology (2009)
